Abstract Number: 1737 • ACR Convergence 2025
CR10049, the first intra-articular Src family kinase inhibitor as a long-acting symptom- and disease-modifying drug for the inflammatory OA phenotype
Background/Purpose: The inflammatory osteoarthritis (OA) phenotype is characterized by the presence of synovial membrane inflammation, pain and pathological changes in joint structure leading to rapid…Abstract Number: 1253 • ACR Convergence 2025
Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Background/Purpose: When treating patients with rheumatological conditions, building a strong physician-patient relationship plays an important role in determining disease outcomes. The Routine Assessment of Patient…Abstract Number: 1229 • ACR Convergence 2025
Extent versus impact: Sex-specific burden of chronic pain in older adults
Background/Purpose: Over one third of older Americans experience chronic pain, accompanied by age-related increases in pain-related activity interference (i.e., pain burden). While pain extent (i.e.,…Abstract Number: 0816 • ACR Convergence 2025
Persistent Pain Despite Inflammatory Control in RA: A Pooled Analysis of 7 RCTs
Background/Purpose: Joint swelling and tenderness are clinical hallmarks of rheumatoid arthritis (RA) and central to disease assessment. Regardless of treatment type, stringent remission based on…Abstract Number: 0325 • ACR Convergence 2025
Knee Symptom Phenotyping Incorporating Pain and Function across Different Levels of WOMAC Function in Two Cohorts: Data from the Multicenter Osteoarthritis Study (MOST) and the Osteoarthritis Initiative (OAI)
Background/Purpose: Knee pain and functional limitations are the most common symptoms of knee OA. Understanding the various patterns of symptoms (i.e., pain and function changes…Abstract Number: 2684 • ACR Convergence 2025
Multimodal Analysis Revealed Altered Brain Connectivity Patterns and Neuroinflammatory Processes in the Background of Difficult-To-Treat Rheumatoid Arthritis
Background/Purpose: Despite advances in rheumatoid arthritis (RA) treatment, 5–20% of patients experience persistent symptoms, particularly pain, and are classified as difficult-to-treat (D2T). Factors such as…Abstract Number: 2093 • ACR Convergence 2025
Association of Acetaminophen Use with Clinical Outcomes in Older Adults with Osteoarthritis: A Global Propensity-Matched Retrospective Cohort Analysis
Background/Purpose: Acetaminophen is widely recommended for osteoarthritis (OA) pain management due to its perceived safety profile. However, its long-term effects on clinical outcomes among older…Abstract Number: 1736 • ACR Convergence 2025
Multi-Model Evaluation of the Impact of CD14 on Synovial Inflammation and Pain During PTOA.
Background/Purpose: Soluble CD14, a co-receptor of inflammatory toll-like receptor signaling that is produced primarily by monocytes/macrophages, is present in synovial fluid in patients with OA…Abstract Number: 1249 • ACR Convergence 2025
Association between Positive Emotions and Physical Function in Early Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease that can significantly impair physical function and quality of life. While physical symptoms such as joint…Abstract Number: 1228 • ACR Convergence 2025
Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Background/Purpose: Evidence-based behavioral treatments for chronic pain are largely inaccessible, particularly to rural patients. This decentralized randomized controlled trial compared the effectiveness of two digital,…Abstract Number: 0813 • ACR Convergence 2025
Impact of Tirzepatide on Musculoskeletal Pain and High-Risk Analgesic Use Among Non-Diabetic Patients with Overweight or Obesity: A Propensity Score-Matched, Active Comparator, New User Study
Background/Purpose: Tirzepatide is a dual GIP/GLP-1 receptor co-agonist approved for weight loss in patients with obesity or body mass index (BMI) > 27 kg/m2 with…Abstract Number: 0320 • ACR Convergence 2025
Transcriptomic profiling of the skeletal muscle of knee OA patients uncovers elevated glucocorticoid and GABA signaling as mediators of skeletal muscle dysfunction in advanced disease
Background/Purpose: Age-related declines in muscle mass and function are leading causes for hospitalizations and mortality in elderly individuals. The risk of developing knee osteoarthritis also…Abstract Number: 2683 • ACR Convergence 2025
Association of Genetic Risk for Pain Intensity with Longitudinal Disease Activity in Rheumatoid Arthritis
Background/Purpose: Guidelines recommend the use of composite scores to evaluate disease activity in RA and inform a treat-to-target approach. It is recognised that patient-reported components…Abstract Number: 2090 • ACR Convergence 2025
Don’t Throw Out X-Rays! Radiographic Osteoarthritis Severity is Prognostic for Onset of Frequent Knee Pain
Background/Purpose: Osteoarthritis (OA) is the most common form of arthritis, a condition associated with substantial disability. Radiographic severity of OA is associated with the presence…Abstract Number: 1735 • ACR Convergence 2025
Endocrine Disruptors Exacerbates Osteoarthritis Pain And Inflammation
Background/Purpose: Osteoarthritis (OA) affects over 590 million individuals globally. Epidemiological data suggest that exposure to environmental pollutants, particularly endocrine-disrupting chemicals (EDCs) such as phthalates, PFAS,…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 44
- Next Page »
